Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 60, Issue 3, 2005, Pages 293-300

  Sharp, Zelton Dave ^a   Bartke, Andrzej ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P70; PROTEIN P85; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CATABOLISM; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; IMMUNOASSAY; LIVER; LONGEVITY; MOUSE; MOUSE STRAIN; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA CAPPING; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

EID: 18244379033     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/60.3.293     Document Type: Article

References (71)

1. Niall HD, Hogan ML, Sauer R, Rosenblum IY, Greenwood FC. Sequences of pituitary and placental lactogenic and growth hormones: evolution from a primordial peptide by gene reduplication. Proc Natl Acad Sci U S A. 1971;68:866-870.
2. Miller WL, Eberhardt NL. Structure and evolution of the growth hormone gene family. Endocr Rev. 1983;4:97-130.
3. Bazan JF. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem Biophys Res Commun. 1989;164:788-795.
4. Ihle JN, Thierfelder W, Teglund S, et al. Signaling by the cytokine receptor superfamily. Ann N Y Acad Sci. 1998;865:1-9.
5. Butler AA, LeRoith D. Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol. 2001;63:141-164.
6. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev. 2001;22:818-835.
7. LeRoith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev, 2001;22:53-74.
8. Touw IP, De Koning JP, Ward AC, Hermans MH. Signaling mechanisms of cytokine receptors and their perturbances in disease. Mol Cell Endocrinol 2000;160:1-9.
9. Coculescu M. Blood-brain barrier for human growth hormone and insulin-like growth factor-I. J Pediatr Endocrinol Metab. 1999;12:113-124.
10. Bartke A, Chandrashekar V, Turyn D, et al. Effects of growth hormone overexpression and growth hormone resistance on neuroendocrine and reproductive functions in transgenic and knock-out mice. Proc Soc Exp Biol Med. 1999;222:113-123.
11. Bartke A, Brown-Borg HM, Bode AM, Carlson J, Hunter WS, Bronson RT. Does growth hormone prevent or accelerate aging? Exp Gerontol. 1998;33:675-687.
12. Kaplan SL. Handbook of Physiology. Kostyo JL, Goodman HM, eds, New York: Oxford University Press; 1999:V: 129-143.
13. Simpson H, Savine R, Sonksen P, et al. Growth hormone replacement therapy for adults: into the new millennium. Growth Horm IGF Res. 2002;12:1-33.
14. Conceicao FL, Bojensen A, Jorgensen JO, Christiansen JS. Growth hormone therapy in adults. Front Neuroendocrinol. 2001;22:213-246.
15. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
16. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002;173:219-238.
17. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res. 2001;33:295-299.
18. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33:300-306.
19. Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 8th ed. Philadelphia: W. B. Saunders Company; 1992
20. Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001;12:252-257.
21. van Buul-Offers S. The effects of pituitary, thyroid, pancreatic and sexual hormones on body length and weight and organ weights of Snell dwarf mice. Growth. 1984;48:101-119.
22. Bartke A, Brown-Borg H, Mattison J, Kinney B, Hauck S, Wright C. Prolonged longevity of hypopituitary dwarf mice. Exp Gerontol. 2001;36:21-28.
23. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999;96:7324-7329.
24. Sjogren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A. 1999;96:7088-7092.
25. Liu JL, Yakar S, LeRoith D. Mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology. 2000;141:4436-4441.
26. Metcalf D, Greenhalgh CJ, Viney E, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000;405:1069-1073.
27. Stickland NC, Crook AR, Sutton CM. Effects of pituitary dwarfism in the mouse on fast and slow skeletal muscles. Acta Anat. 1994;151:245-249.
28. van Buul-Offers SC, Reijnen-Gresnigt MG, Hoogerbrugge CM, Bloemen RJ, Kuper CF, Van den Brande JL. Recombinant insulin-like growth factor-II inhibits the growth-stimulating effect of growth hormone on the liver of Snell dwarf mice. Endocrinology. 1994;135:977-985.
29. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472-1487.
30. Kozma SC, Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays. 2002;24:65-71.
31. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657.
32. Fumagalli S, Thomas G. Translational Control of Gene Expression. 2nd Ed. Sonenberg N, Hershey JWB, Mathews M, eds. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2000:695-717.
33. Pause A, Belsham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371:762-767.
34. Lin TA, Kong X, Haystead TA, et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science. 1994;266:653-656.
35. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol Cell. 1999;3:707-716.
36. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 1999;68:913-963.
37. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807-826.
38. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-365.
39. Dennis PB, Fumagalli S, Thomas G. Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev. 1999;9:49-54.
40. Rohde J, Heitman J, Cardenas ME. The TOR kinases link nutrient sensing to cell growth. J Biol Chem. 2001;276:9583-9586.
41. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-262.
42. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratories Press; 1988.
43. Reinhard C, Fernandez A, Lamb NJ, Thomas G. Nuclear localization of p85s6k: functional requirement for entry into S phase. Embo J. 1994;13:1557-1565.
44. Mothe-Satney I, Yang D, Fadden P, Haystead TA, Lawrence JC Jr. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol. 2000;20:3558-3567.
45. Korner A. Growth hormone effects on RNA and protein synthesis in liver. J Cell Physiol. 1965;66(Suppl 1):153-162.
46. Mellet J. Etude de l'effectif ribosomique du foie chez la souris normale et chez la souris naine. Biochimie. 1973;55:189-194.
47. Stolovich M, Tang H, Hornstein E, et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol. 2002;22:8101-8113.
48. Bates PC, Holder AT. The anabolic actions of growth hormone and thyroxine on protein metabolism in Snell dwarf and normal mice. J Endocrinol. 1988;119:31-41.
49. van Buul-Offers S, Van den Brande JL. Cellular growth in organs of dwarf mice during treatment with growth hormone, thyroxine and plasma fractions containing somatomedin activity. Acta Endocrinol (Copenh). 1982;99:150-160.
50. Skrtic S, Wallenius K, Sjogren K, Isaksson OG, Ohlsson C, Jansson JO. Possible roles of insulin-like growth factor in regulation of physiological and pathophysiological liver growth. Horm Res. 2001;55:1-6.
51. Liu JL, LeRoith D. Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. Endocrinology. 1999;140:5178-5184.
52. Wanke R, Wolf E, Hermanns W, Folger S, Buchmuller T, Brem G. The GH-transgenic mouse as an experimental model for growth research: clinical and pathological studies. Horm Res. 1992;37(Suppl 3):74-87.
53. Quaife CJ, Mathews LS, Pinkert CA, Hammer RE, Brinster RL, Palmiter RD. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology. 1989;124:40-48.
54. Rooyackers OE, Nair KS. Hormonal regulation of human muscle protein metabolism. Annu Rev Nutr. 1997;17:457-485.
55. Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, Schiaffino S. A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc Natl Acad Sci U S A. 2002;99:9213-9218.
56. Anderson NG. Simultaneous activation of p90rsk and p70s6k S6 kinases by growth hormone in 3T3-F442A preadipocytes. Biochem Biophys Res Commun. 1993;193:284-290.
57. Kilgour E, Gout I, Anderson NG. Requirement for phosphoinositide 3-OH kinase in growth hormone signalling to the mitogen-activated protein kinase and p70s6k pathways. Biochem J. 1996;315(Pt 2): 517-522.
58. MacKenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RG, Houslay MD. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc Natl Acad Sci U S A. 1998;95:3549-3554.
59. Mattison JA, Wright C, Bronson RT, Roth GS, Ingram DK, Bartke A. Studies of aging in Ames dwarf mice: effects of caloric restriction. J Amer Aging Assoc. 2000;23:9-16.
60. Pan D, Dong J, Zhang Y, Gao X. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol. 2004;14:78-85.
61. Mobbs CV, Bray GA, Atkinson RL, et al. Neuroendocrine and pharmacological manipulations to assess how caloric restriction increases life span. J Gerontol A Biol Sci Med Sci. 2001;56(Spec No. 1):34-44.
62. Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology. 2000;141:2608-2613.
63. Brown-Borg HM, Borg KE, Meliska CJ, Bartke A. Dwarf mice and the ageing process. Nature. 1996;384:33.
64. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci U S A. 2001;98:6736-6741.
65. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003;299:572-574.
66. Tatar M, Kopelman A, Epstein D, Tu MP, Yin CM, Garofalo RS. A mutant drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science. 2001;292:107-110.
67. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421:182-187.
68. Bartke A, Wright JC, Mattison JA, Ingram DK, Miller RA, Roth GS. Extending the lifespan of long-lived mice. Nature. 2001;414:412.
69. Clancy DJ, Gems D, Harshman LG, et al. Extension of life-span by loss of CHICO, a drosophila insulin receptor substrate protein. Science. 2001;292:104-106.
70. Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003;426:620.
71. Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14:885-890.